Skip to main content
OpenTrials
Completed

NCT Number: NCT02727270

Measuring Cortisol Levels in Persons With Parkinson's (PD)

The objective of this study is to evaluate the cortisol awakening response with persons with Parkinsons Disease (PD), Huntingtons Disease (HD), and controls. These data are desired so experience can be gained with measuring stress levels subjectively and objectively in persons with PD, HD, and controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Chorea Cognition Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dementia Dyskinesias Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Huntington Disease Mental Disorders Movement Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Oregon Health & Science Universtiy, Portland, Oregon, United States

Loading trial locations.

About this study

Telephone consent will be obtained.

Participants will collect saliva at twelve time points - four times a day for three days.

Visits will be conducted virtually (over the internet).

The virtual visit is to assess Parkinson's or Huntington's disease status, stress, mood, and quality of life.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Group (3) Inclusion:

  • No significant neurological disorder
  • PSS score of greater than or equal to 13.

Group (5) Inclusion:

  • HD diagnosis or HD gene carrier
  • a Perceived Stress Scale (PSS) score higher than or equal to 13.

Group (6) Inclusion:

  • HD diagnosis or HD gene carrier
  • PSS score lower than 13

Group (7) Inclusion:

  • PD diagnosis
  • Prior completion of the study.

Exclusion criteria

  • The use of medications known to effect cortisol levels (estrogen, synthetic glucocorticoids, androgens, phenytoin, spironolactone, prednisone, prednisolone, and hydrocortisone).

Treatment and study plan

NO intervention - observational study

Other

No Intervention - Observational Study

Primary outcomes

  1. Awakening Salivary Cortisol level (ug/dL) Response

    Time frame: Collected upon awakening and 30 minutes after awakening

    Salivary Cortisol level (ug/dL) Response is the change in cortisol between awakening and 30 minutes after awakening.

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Collaborators

  • Huntington's Disease Society of America
  • Oregon Clinical and Translational Research Institute
  • Portland VA Medical Center

Registry information

Acronym: CORT-PD

Important dates

Study start
2016
Primary completion
2023
Study completion
2023
First posted
Apr 4, 2016
Registry last updated
Dec 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.